A Phase II Trial of Didemnin B (NSC #335319) in Patients with Advanced Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 19, Issue 2, 1996, Pages 184-186

  Malfetano, John H ^a,f   Blessing, John A ^b   Homesley, Howard D ^c   Look, Katherine Y ^d   McGehee, Ramon ^e  

^a ALBANY MEDICAL CENTER   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c WAKE FOREST BAPTIST HEALTH   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^f ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDEMNIN B; NSC 335319; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; HYPERGLYCEMIA; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LIVER TOXICITY; NEPHROTOXICITY; NEUROTOXICITY; PAIN; PHASE 2 CLINICAL TRIAL; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIEMETICS; ANTINEOPLASTIC AGENTS; BLOOD COAGULATION; CARCINOMA, SQUAMOUS CELL; DEPSIPEPTIDES; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MIDDLE AGED; NAUSEA; NEOPLASM RECURRENCE, LOCAL; PEPTIDES, CYCLIC; RADIATION-SENSITIZING AGENTS; REMISSION INDUCTION; UTERINE CERVICAL NEOPLASMS; VOMITING;

EID: 0029927462     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199604000-00019     Document Type: Article

References (10)

1. Rinehart KL Jr, Gloer JB, Hughes RG Jr, et al. Didemnins: antiviral and antitumor depsipeptides from a Caribbean tunicate. Science 1981;212:933-5.
2. Crampton SL, Adams EG, Kuentzel SL, et al. Biochemical and cellular effects of Didemnins A and B. Cancer Res 1984;44:1796-801.
3. Rinehart KL Jr, Gloer JB, Wilson GR, et al. Antiviral and antitumor compounds from tunicates. Fed Proc 1983;42:87-90.
4. Montgomery DW, Zukoski CF, Didemnin B: a new immunosuppressive cyclic peptide with potent activity in vitro and in vivo. Transplantation 1985;40:49-56.
5. Montgomery DW, Celniker A, Zukoski CF, Didemnin B: an immunosuppressive cyclic peptide that stimulates murine menagglutinating antibody responses and induces leukocytosis in vivo. Transplantation 1987;43:133-9.
6. Crampton SL, Bhuyan BK, Li LH. Biochemical and cell biological effects of Didemnins A and B. Proc Am Assoc Cancer Res 1982;23:203.
7. Jian TL, Liu RH, Salmon SE. Antitumor effect of Didemnin B in human tumor stem cell assay. Cancer Chemother Pharmacol 1983;11:1-4.
8. Division of Cancer Treatment, National Cancer Institute. Annual report to the Food and Drug Administration: Didemnin B. 1986.
9. Malfetano JH, Blessing JA, Jacobs AJ. A Phase II trial of Didemnin B (NSC #335319) in patients with previously treated epithelial ovarian cancer. A Gynecologic Oncology Group Study. Am J Clin Oncol 1993;15:47-9.
10. Blessing JA. Design, analysis and interpretation of chemotherapy trials in gynecologic cancer. In Deppe G, ed. Chemotherapy of gynecologic cancer. 2nd ed. New York: Alan R. Liss, 1990: 63-97.